.png)
An artistic rendering of an extracellular vesicle.
Image Credit: Jana Zárubová, Li Lab
Scientific Frontline: Extended "At a Glance" Summary: Stem Cell-Derived Extracellular Vesicles
The Core Concept: Extracellular vesicles, which are naturally released by pluripotent stem cells, possess powerful immune-regulating properties. When deployed therapeutically, these nanoscale particles can modulate immune cells and help protect insulin-producing pancreatic cells from being destroyed.
Key Distinction/Mechanism: Unlike traditional insulin therapy, which only manages symptoms, these vesicles address the root autoimmune cause by promoting the formation of regulatory T cells. Delivered via an injectable hydrogel, they are gradually released over several days to interact with lymph nodes and provide systemic immune protection.
Origin/History: Inspired by the way a mother's immune system tolerates a developing embryo, UCLA researchers published these findings in Nature Nanotechnology in late 2026.
Major Frameworks/Components:
- Induced pluripotent stem cells (iPSCs): Serve as a highly scalable source of extracellular vesicles with robust anti-inflammatory properties.
- Regulatory T cells: Specialized immune cells promoted by the vesicles to prevent autoimmune attacks on host tissues.
- Hydrogel delivery system: An injectable matrix designed to solve the rapid clearance of extracellular vesicles, providing sustained release.
- Three-dimensional cell culture: A method of growing stem cells in suspended liquid clusters rather than flat, two-dimensional surfaces, increasing vesicle yield by 3.4-fold without sacrificing quality.
Branches of Science: Nanomedicine, Stem Cell Biology, Immunology, Bioengineering, Endocrinology.
Future Application: The therapeutic delivery of iPSC-derived extracellular vesicles could be used to protect remaining functional pancreatic cells in early-stage type 1 diabetes. It may also prevent immune rejection of transplanted insulin-producing cells, and it could be adapted to treat other autoimmune diseases.
Why It Matters: This nanoparticle approach actively suppresses the underlying autoimmune assault on the pancreas. By halting the destruction of insulin-producing cells, it offers a novel strategy to delay or prevent the progression of type 1 diabetes, moving beyond mere symptom management.
In people with type 1 diabetes, the immune system mistakenly identifies insulin-producing cells in the pancreas as foreign and attacks them, leaving the body unable to properly regulate blood glucose levels. While insulin therapy helps manage the disease, it does not stop the underlying immune attack.
UCLA researchers have identified a mechanism to protect these cells by utilizing extracellular vesicles—nanoscale particles naturally released by nearly all cell types that facilitate intercellular signaling.
In a study published in Nature Nanotechnology, the team found that vesicles produced by certain types of stem cells can help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in mice. The findings suggest a possible strategy for preserving insulin-producing cells before they are destroyed.
Harnessing stem cells' natural ability to regulate immunity
The research was inspired in part by immunological tolerance during pregnancy: A mother's immune system generally tolerates a developing embryo, even though it carries genetic material from the father that her immune system could recognize as foreign.
Senior author Song Li, associate dean for graduate and professional education and a professor of bioengineering at the UCLA Samueli School of Engineering and a member of the UCLA Broad Stem Cell Research Center, noted that understanding the immunological tolerance of an embryo during pregnancy could inform treatments for immune-mediated diseases.
Based on this precedent of immunological tolerance, the research team investigated whether extracellular vesicles released by pluripotent stem cells—which share characteristics with cells found in early embryonic development—might also possess immune-regulating properties.
The researchers compared vesicles from embryonic stem cells and induced pluripotent stem cells, or iPSCs, with those from mesenchymal stem cells, which have been widely studied for their ability to regulate inflammation.
In experiments using mouse and human immune cells, vesicles from both types of pluripotent stem cells showed stronger anti-inflammatory effects than those from mesenchymal stem cells. They also promoted the formation of regulatory T cells, specialized immune cells that help prevent the immune system from attacking the body's own tissues.
Further analysis showed that the vesicles carry distinctive proteins, lipids, and genetic material that may contribute to their immune-regulating properties, providing insight into how these naturally produced nanoparticles influence immune cells.
Protecting insulin-producing cells
To test whether these immune-regulating effects could help prevent diabetes, the researchers introduced immune cells that attack insulin-producing pancreatic cells into mice, and then treated the animals with extracellular vesicles derived from iPSCs.
Because extracellular vesicles are rapidly cleared from the injection site, the team developed an injectable hydrogel that gradually releases them over several days.
The treatment was injected beneath the skin near the neck, where the vesicles could interact with immune cells in nearby lymph nodes. These immune cells could then circulate throughout the body, potentially reducing harmful immune activity in the pancreas.
The researchers found that two treatments with extracellular vesicles, either alone or delivered through the hydrogel, significantly delayed the onset of diabetes compared with untreated controls. At the end of the 90-day study, 55% of mice receiving vesicles in the hydrogel remained diabetes-free.
Mice receiving vesicles in the hydrogel also had more regulatory T cells in their lymph nodes and retained more insulin-producing pancreatic tissue than control animals.
Li noted the significance of achieving systemic immunomodulation via a localized injection.
Scalability of Extracellular Vesicle Production
The researchers also addressed a major obstacle to developing extracellular vesicle-based treatments: producing sufficient quantities of consistent, high-quality particles.
Rather than growing stem cells on flat laboratory surfaces, the team grew them in three-dimensional clusters suspended in gently moving liquid. This approach increased vesicle production 3.4-fold per million cells while preserving important characteristics of the particles.
Because iPSCs can multiply extensively in the laboratory, they could provide a more consistent and scalable source of therapeutic vesicles than adult stem cells, whose growth potential is more limited.
The approach remains experimental, and further studies are needed to determine whether it would be safe and effective in people.
Li envisions the greatest potential for patients in earlier stages of type 1 diabetes, when some insulin-producing cells remain functional.
Li noted that regulating immune cells during the early stages of type 1 diabetes could preserve the functionality of the remaining insulin-producing cells.
In more advanced disease, immune regulation alone would not replace cells that have already been lost. However, the approach could potentially help prevent immune rejection of transplanted insulin-producing cells.
The team hopes to test the approach in larger animal models and investigate appropriate dosing, long-term effectiveness, and whether the treatment could weaken the body's defenses against infection.
Beyond diabetes, the findings could inform research into other autoimmune diseases and strategies for protecting transplanted cells from immune rejection.
Reference material: Extracellular Vesicles (Exosomes)
Funding: The research was supported by the California Institute for Regenerative Medicine, the National Institutes of Health, a UCLA Broad Stem Cell Research Center Innovation Award, and Breakthrough T1D.
Published in journal: Nature Nanotechnology
Authors: Jana Zarubova, Mohammad Mahdi Hasani-Sadrabadi, Yutong Wu, Graciel Diamante, Jenny Cheng, Soomin Park, Xiao Han, Fatemeh Sadat Majedi, Li Yang, Olivia Wang, In Sook Ahn, Cade M. Matherne, Jia Fan, Jianyi Zhang, Xiaojun Lance Lian, Zhen Gu, Manish J. Butte, Reza Ardehali, Peter C. Butler, Tony Ye Hu, Louis-S. Bouchard, Xia Yang, and Song Li
Source/Credit: University of California, Los Angeles / Health | Tiare Dunlap
Edited by: Scientific Frontline
Reference Number: nt111826_01
.png)